North America Enteral Nutrition Market
Published On: Mar 2024
Published On: Mar 2024
At 6.2% CAGR, the North America Enteral Nutrition Market is Projected to be Worth US$ 5,187.48 Million by 2030, Says Business Market Insights
According to Business Market Insights research, the North America enteral nutrition market was valued at US$ 3,206.58 million in 2022 and is expected to reach US$ 5,187.48 million by 2030, registering a CAGR of 6.2% from 2022 to 2030. Specific formulations and plant-based nutrition products and increasing prevalence of gastrointestinal diseases are among the critical factors attributed to the North America enteral nutrition market expansion.
There is a surge in the demand for products that help consumers proactively manage their health, especially those focused on specific needs in terms of energy levels, immunity, and disease treatment. Functionality and specific formulations of enteral products do not interfere with the existing treatments of patients. The macro-nutrient and micronutrient formulations of enteral nutrition and their applications vary based on the disease under consideration. Isocaloric enteral nutrition formulation (1 kcal/ml) is generally prescribed to achieve estimated or measured caloric goals, while energy-dense formulae (>1 kcal/ml) are prescribed to increase calorie delivery in patients with gastrointestinal dysfunction.
Standardized enteral nutrition products contain fixed constituents and are designed to meet an average patient's nutritional requirements, considering different requirements in different age groups. For example, Peptamen Formula (Nestle) is the only peptide-based formula with enzymatically hydrolyzed 100% whey protein that helps overcome tube-feeding intolerance. Such tube-feeding formulas are specialized enteral nutrition products designed to support absorption and overcome tolerance mechanisms in individuals with gastrointestinal disorders.
Further, a surge in the number of people turning to plant-based food triggers the demand for plant-based nutrition products worldwide. People are becoming increasingly intolerant of artificial/synthetically sourced ingredients used in higher numbers, which may lead to adverse reactions. The Innova Consumer Survey 2020 showed that health, diet variety, sustainability, and taste are among the top reasons why people consider plant-based alternatives. Abbott adds that consumers and patients relying on tube feeding are no exception to this trend. The American Medical Association is calling on healthcare facilities to introduce plant-based meal options to improve patients' health. California, New York, and the District of Columbia, among others, have asked hospitals to make healthy, plant-based meals available to all patients. Companies in the enteral nutrition market anticipate that a growing focus on healthy foods would translate into a preference for healthier nutrition products. As a result, new companies such as Kate Farms, Functional Formularies, and Real Food Blends have developed more natural, plant-based enteral products. In August 2021, Kate Farms launched the first closed feeding system delivering plant-based formulas in ready-to-hang bags of 1 L capacity. Kate Farms Standard 1.4 plain and Peptide 1.5 plain formulations are plant-based, organic, calorically dense products that are used as a sole source of supplemental nutrition in tube feeding. In September 2021, Abbott introduced a portfolio of plant-based proteins and organic food ingredients for children and adults.
Therefore, functional, patient-centric formulations and plant-based nutrition products are the prime emerging trends in the enteral nutrition market.
On the contrary, complications associated with enteral feeding systems hampers the growth North America enteral nutrition market.
Based on product type, the North America enteral nutrition market is bifurcated into general and disease specific. The general segment held 57.3% share of the North America enteral nutrition market in 2022, amassing US$ 1,837.14 million. It is projected to garner US$ 2,951.22 million by 2030 to expand at 6.1% CAGR during 2022-2030.
In terms of application, the North America enteral nutrition market is segmented into gastrointestinal disorders, metabolic/inborn errors of metabolism, food allergy, renal disease, liver disease, oncology, neurology, and others. The gastrointestinal disorders segment held 30.3% share of the North America enteral nutrition market in 2022, amassing US$ 970.02 million. It is projected to garner US$ 1,557.36 million by 2030 to expand at 6.1% CAGR during 2022-2030.
Based on age group, the North America enteral nutrition market is bifurcated into adult and pediatric. The adult segment held 85.0% share of the North America enteral nutrition market in 2022, amassing US$ 2,725.86 million. It is projected to garner US$ 4,359.92 million by 2030 to expand at 6.0% CAGR during 2022-2030.
By distribution channel, the North America enteral nutrition market is segmented into hospital pharmacies, retail stores, e-commerce, and others. The hospital pharmacies segment held 57.9% share of North America enteral nutrition market in 2022, amassing US$ 1,856.77 million. It is projected to garner US$ 2,953.10 million by 2030 to expand at 6.0% CAGR during 2022-2030.
Based on country, the North America enteral nutrition market is categorized into the US, Canada, and Mexico. The US held 83.4% share of North America enteral nutrition market in 2022, amassing US$ 2,674.29 million. It is projected to garner US$ 4,370.23 million by 2030 to expand at 6.3% CAGR during 2022-2030.
Key players operating in the North America enteral nutrition market are Abbott Laboratories, Nestle SA, Danone SA, Fresenius SE & Co KGaA, B Braun SE, Dr Schar AG, Reckitt Benckiser Group Plc, Nutritional Medicinals LLC, Kate Farms Inc, Royal FrieslandCampina NV, Arla Foods amba, Perrigo Co Plc, and Fonterra Co-Operative Group Ltd, among others.
E 1803, Panchshil Towers, Vagholi, Haveli, Pune- 412207, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
